June 13, 2016
3 min watch
Save

VIDEO: A look at results from phase 3 studies of baricitinib for RA treatment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

LONDON — At the EULAR Annual Congress, Peter C. Taylor, MA, PhD, FRCP, discussed a study which looked at phase 3 studies of baricitinib. He said the patient-reported outcomes showed there were statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA).